

## **ABSTRACT OF THE DISCLOSURE**

The invention provides a crystalline salt form of a novel  $\beta_2$  adrenergic receptor  
5 agonist. The invention also provides pharmaceutical compositions comprising the  
crystalline form, formulations containing the pharmaceutical compositions, methods of  
using the crystalline salt form to treat diseases associated with  $\beta_2$  adrenergic receptor  
activity, and processes useful for preparing such a crystalline compound.

10